Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-09-08

FDA Approved: ADAKVEO — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for ADAKVEO (crizanlizumab) submitted by Novartis Pharmaceuticals Corporation, potentially expanding or updating the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADAKVEO (crizanlizumab)

Snippet

SUPPL AP for ADAKVEO (CRIZANLIZUMAB)